Does SummaCare Cover Propecia?

What Is Propecia and Why Does Coverage Get Complicated?

Propecia is the brand name for finasteride 1 mg, a type II 5-alpha-reductase inhibitor approved by the FDA in 1997 for androgenetic alopecia (male pattern hair loss) in men. [1] The drug reduces scalp dihydrotestosterone (DHT) by roughly 60%, slowing follicle miniaturization. Insurance coverage is complicated because the FDA indication is cosmetic in the eyes of most payers. Commercial health plans are not required by federal law to cover cosmetic treatments, so they routinely exclude or restrict finasteride for hair loss even when they cover the identical molecule at higher doses for benign prostatic hyperplasia (BPH).

The Cosmetic Exclusion Problem

The ACA (Affordable Care Act) mandates coverage for preventive services rated "A" or "B" by the U.S. Preventive Services Task Force, but androgenetic alopecia carries no such USPSTF rating. [2] That absence gives insurers legal room to classify finasteride 1 mg as cosmetic and exclude it from the formulary entirely, regardless of the psychological burden hair loss places on patients.

Brand vs. Generic: A Critical Distinction

Brand Propecia and generic finasteride 1 mg are bioequivalent. The FDA's Orange Book confirms multiple generic manufacturers hold approved ANDAs. [3] Because generic finasteride has been available since 2006, brand Propecia commands almost no market share in covered pharmacy benefits. When SummaCare does list finasteride for hair loss, it lists the generic, not the brand. Asking a pharmacist to run "finasteride 1 mg" rather than "Propecia" is the first practical step before assuming no coverage exists.

How SummaCare Builds Its Drug Formulary

SummaCare is a regional Ohio-based health insurer offering HMO, PPO, and Medicare Advantage plans. Each product line maintains a separate formulary that is updated annually. Understanding the structure explains why two members with "SummaCare coverage" can receive entirely different answers about finasteride.

Formulary Tiers and What They Mean

SummaCare's commercial formularies typically run four to five tiers. Tier 1 covers preferred generics at the lowest copay, often $5 to $15. Tier 2 covers non-preferred generics. Tier 3 and above cover preferred and non-preferred brand-name drugs at much higher cost sharing. Brand Propecia, when it appears at all, lands on Tier 3 or Tier 4 given its cosmetic classification. Generic finasteride for hair loss may be listed on Tier 2 on select employer-group plans, or it may be excluded entirely under a "cosmetic drug" carve-out.

How to Look Up Your Specific Plan

The only authoritative source for your plan's formulary is the Evidence of Coverage (EOC) document or the online drug search tool tied to your specific group number and plan year. SummaCare's member portal at summacare.com allows formulary searches by drug name and plan. Before calling a pharmacy benefits manager, download your Summary of Benefits and look for language like "cosmetic drugs excluded" or "hair loss treatments excluded." That language, when present, overrides any tier listing.

Medicare Advantage Plans and Part D Rules

SummaCare Medicare Advantage plans follow CMS Part D rules. CMS explicitly lists "drugs used for cosmetic purposes or hair growth" as a non-covered category under Part D. [4] That means Medicare Advantage members have no federal pathway to Part D coverage for finasteride prescribed solely for hair loss. Some Medicare Advantage plans offer supplemental over-the-counter (OTC) benefits, but finasteride is a prescription drug and does not qualify under those OTC allowances.

Prior Authorization for Finasteride Under SummaCare

Even when generic finasteride 1 mg appears on a SummaCare commercial formulary, the plan may flag it for prior authorization (PA). PA requirements exist because the same molecule is prescribed for both BPH and hair loss, and the plan wants to confirm the indication before paying.

What PA Reviewers Look For

A PA reviewer evaluating a finasteride 1 mg request for androgenetic alopecia typically checks: the documented diagnosis code (L64.x for androgenic alopecia), patient sex (Propecia is approved only in men; it is teratogenic in women of childbearing potential per FDA labeling), [1] and whether any "step therapy" requirement applies, such as topical minoxidil tried first.

How to Submit a Strong PA Request

Prescribers should document the following to maximize PA approval odds:

• Confirmed diagnosis with ICD-10 code L64.9 (androgenic alopecia, unspecified) or L64.8
• Duration of hair loss and degree of progression using the Norwood-Hamilton scale
• Prior use of 5% minoxidil topical solution for at least 4 months with documented response or intolerance
• Any psychosocial impact noted in the clinical record

The American Academy of Dermatology guidelines recommend finasteride 1 mg daily as a first-line systemic option for male androgenetic alopecia, describing it as having "high-quality evidence" for slowing hair loss and promoting regrowth. [5] Including this guideline reference in a PA letter gives the request clinical grounding that reviewers recognize.

Timelines and What Happens if PA Is Denied

Standard PA decisions under commercial plans must be returned within 72 hours for urgent requests and 15 days for standard non-urgent requests under Ohio insurance regulations. If SummaCare denies the PA, the denial letter must explain the specific reason and outline the appeals process.

Appealing a SummaCare Denial for Propecia or Finasteride

A denial is not a final answer. Ohio law and federal ACA regulations give members the right to an internal appeal and, if that fails, an independent external review.

Internal Appeal

File the internal appeal within the timeframe stated on the denial letter (typically 180 days for commercial plans). The appeal packet should include:

• A letter from the prescribing physician explaining medical necessity beyond cosmetics, referencing quality-of-life data
• Published clinical evidence (see the Phase III trial data below)
• Any documentation of psychological distress, particularly if a mental health provider has documented depression or anxiety tied to hair loss

External Review

If the internal appeal fails, Ohio members may request an Independent Review Organization (IRO) review through the Ohio Department of Insurance. The IRO decision is binding on SummaCare. External review is particularly worth pursuing when the denial rests solely on a cosmetic exclusion and the prescriber has documented medical necessity.

The HealthRX clinical team uses the following decision framework when advising patients navigating SummaCare finasteride denials:

Step 1. Confirm the exact formulary status using the plan's online tool with the specific group number. Step 2. If excluded as cosmetic, request the denial in writing and obtain the specific exclusion language. Step 3. Assess whether finasteride 5 mg (Proscar) is covered under a BPH indication and discuss pill-splitting with a physician. Step 4. If PA is required and submitted, attach the AAD guideline reference and Norwood scale documentation. Step 5. If denied, file the internal appeal within 30 days for the fastest turnaround. Step 6. If the internal appeal fails, file for IRO external review through the Ohio Department of Insurance. Step 7. While appeals proceed, use a GoodRx or Mark Cuban Cost Plus Drugs coupon for finasteride 1 mg (prices as low as $12 for 30 tablets).

Clinical Evidence Supporting Finasteride for Androgenetic Alopecia

Understanding the strength of the clinical data helps patients and prescribers make informed decisions and write effective appeal letters.

Phase III Key Trials

The original FDA-approval trials for Propecia enrolled 1,553 men with mild to moderate androgenetic alopecia. After 2 years of finasteride 1 mg daily versus placebo, the finasteride group showed a 48% increase in hair count in the targeted scalp area, and 83% of finasteride-treated men showed no further hair loss versus 28% in the placebo group. [6] These results were published in the Journal of the American Academy of Dermatology and remain the foundational evidence base cited by the AAD guideline.

Long-Term Durability

A 5-year open-label extension of those key trials showed that men who continued finasteride 1 mg maintained hair count above baseline, while men who switched to placebo lost the gains within 12 months. [7] That durability profile is clinically meaningful: the drug's benefits are sustained only with continuous use, which gives prescribers a legitimate "maintenance therapy" framing for appeal letters.

DHT Suppression Mechanism

Finasteride inhibits type II 5-alpha-reductase, the enzyme that converts testosterone to DHT in the scalp. DHT is the primary androgen responsible for follicle miniaturization in genetically predisposed men. [8] At 1 mg daily, finasteride reduces serum DHT by approximately 60% and scalp DHT by approximately 64%, as measured in pharmacodynamic studies included in the FDA label. [1] This mechanism-based evidence supports the argument that treatment is pathophysiological, not purely cosmetic.

Sexual Side Effects: What the Data Actually Show

The Phase III trials reported sexual adverse events (decreased libido, ejaculatory dysfunction, erectile dysfunction) in 3.8% of finasteride-treated men versus 2.1% of placebo-treated men. [6] A subset of men report persistent sexual dysfunction after discontinuation, a phenomenon discussed in case series. [9] Any coverage appeal letter should not minimize these risks; instead, it should note that a physician has discussed them and the patient has given informed consent, reinforcing that this is a supervised medical decision.

The Proscar Loophole: Finasteride 5 mg for BPH

Finasteride 5 mg (brand name Proscar) is FDA-approved for BPH. SummaCare commercial plans are far more likely to cover finasteride 5 mg under a BPH diagnosis than to cover finasteride 1 mg for hair loss. Some prescribers and patients use pill-splitting to obtain 1 mg doses from 5 mg tablets, reducing cost by approximately 75%.

Is Pill-Splitting Safe for Finasteride?

Finasteride tablets are not enteric-coated or extended-release, so splitting them does not destroy the delivery mechanism. The FDA's guidance on drug product splitting notes that immediate-release tablets without special coatings are generally suitable for splitting. [10] The primary concern is dose precision; a clean pill splitter gives doses within approximately 10 to 15% of target, which is within the therapeutic window given finasteride's flat dose-response curve for DHT suppression across the 0.2 mg to 5 mg range. [1]

Coverage and Prescribing Considerations

A prescriber writing finasteride 5 mg for a patient who has both BPH symptoms and androgenetic alopecia can legitimately bill the BPH diagnosis. For patients without BPH, prescribing Proscar for hair loss only is off-label, and some payers audit for diagnosis-drug mismatch. Patients should discuss this approach transparently with their physician. Using finasteride 5 mg off-label for hair loss without a BPH diagnosis does not increase safety risk, but it may trigger a pharmacy claim rejection if the plan's coverage is tied to the BPH indication.

Cost Without Insurance: Making Finasteride Affordable

Even if SummaCare does not cover finasteride, the drug is inexpensive through the right channels.

Discount Programs

• GoodRx: Finasteride 1 mg, 30 tablets: approximately $12 to $20 at major Ohio pharmacies as of early 2025.
• Mark Cuban Cost Plus Drugs: Finasteride 1 mg, 30 tablets: listed at approximately $6 plus dispensing fees.
• Manufacturer coupons: Brand Propecia coupons are available but typically apply only when insurance is not used.

Telehealth Subscriptions

Several telehealth platforms offer finasteride 1 mg as part of a monthly subscription that includes the physician visit and medication. Prices range from $20 to $40 per month. These subscriptions function outside insurance billing entirely, which sidesteps the coverage question for patients willing to pay directly. HealthRX offers a finasteride subscription that includes quarterly physician check-ins, scalp progress tracking, and lab monitoring per standard of care.

When Does Insurance Coverage Actually Save Money?

If a SummaCare plan covers generic finasteride on Tier 1 at a $10 copay, the savings versus a $12 GoodRx price are modest. The real calculus involves whether using the prescription benefit counts toward the annual deductible or out-of-pocket maximum. For patients with high medical costs, routing finasteride through insurance may matter even at similar dollar amounts per fill.

Minoxidil as a Covered Alternative

Topical minoxidil 2% and 5% solutions became available over the counter in 1996. Because OTC drugs are never processed through a pharmacy benefit, SummaCare does not cover topical minoxidil. Oral minoxidil at low doses (0.625 mg to 2.5 mg daily) is an off-label use for hair loss that has gained traction in dermatology. [11] Oral minoxidil is a prescription drug, and some commercial plans cover it under a cardiovascular indication (it was originally approved as an antihypertensive), though coverage for the hair-loss indication is inconsistent.

Comparing Finasteride and Minoxidil Efficacy

A 48-week randomized trial comparing finasteride 1 mg to topical minoxidil 5% in men with androgenetic alopecia found finasteride produced greater hair count increases (17.3 hairs per cm2 vs. 12.8 hairs per cm2, P<0.05). [12] Combination therapy produced additive benefit. The AAD guideline rates both agents as having strong evidence but notes they work through different mechanisms, making combination a reasonable clinical choice. [5]

Special Populations: Women and SummaCare Coverage

Finasteride 1 mg is FDA-approved only for men. Women of childbearing potential must not handle crushed or broken finasteride tablets due to teratogenicity risk. [1] Off-label use in postmenopausal women with androgenetic alopecia has been studied; a small randomized trial (N=36) showed finasteride 1 mg daily produced no significant benefit in postmenopausal women over 12 months compared with placebo. [13] Larger doses (2.5 mg to 5 mg) have shown modest benefit in some observational studies of postmenopausal women, but evidence is limited. SummaCare would apply the same cosmetic exclusion logic to any finasteride prescription for female hair loss.

How to Talk to SummaCare Member Services About Finasteride

Calling the member services number on the back of your SummaCare ID card is often the fastest way to get a definitive formulary answer. Before calling, gather:

1. Your group number and member ID
2. The exact drug name and strength you want covered (finasteride 1 mg or finasteride 5 mg)
3. The ICD-10 diagnosis code your prescriber will use (L64.9 for androgenetic alopecia)
4. The NPI number of your prescribing physician

Ask the representative specifically: "Is finasteride 1 mg on my plan's formulary for diagnosis code L64.9, and if so, what tier and is prior authorization required?" Document the representative's name, the date, and the reference number for the call. That record becomes useful if a claim is later denied after a verbal confirmation of coverage.